Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Olorofim · F-901318

Small molecule · developed by F2G

Phase 3 Most advanced trial
1 Registered trials

What is Olorofim?

Olorofim is a systemic antifungal agent studied in invasive aspergillosis and other invasive fungal infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
F-901318
Drug type
Small molecule
Therapy area
Infectious disease
Developer
F2G Ltd
In trials of
IQV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
T34SH2H9HI

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05101187 Phase 3 Invasive Aspergillosis Active not recruiting IQV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Invasive Aspergillosis

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.